Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;26(7):e70157.
doi: 10.1002/acm2.70157.

Analysis of treatment planning time and optimization parameters for inverse planning for intracavitary and interstitial brachytherapy in uterine cervical cancer

Affiliations

Analysis of treatment planning time and optimization parameters for inverse planning for intracavitary and interstitial brachytherapy in uterine cervical cancer

Jun Tomihara et al. J Appl Clin Med Phys. 2025 Jul.

Abstract

Purpose: This study aimed to investigate the effect of inverse planning parameters on dose-volume indices in brachytherapy for uterine cervical cancer.

Methods: Fourteen consecutive patients with cervical cancer who received intracavitary and interstitial brachytherapy (IC/ISBT) were selected. Tandem, ovoid, and interstitial needles were used in all cases. The evaluation plans were recalculated from the first fraction of clinical brachytherapy plans. The correlation between the 11 dose optimization parameters of inverse planning and the 13 dose-volume indices was evaluated. The parameters were adjusted in five levels, and dose optimization was performed in hybrid inverse planning optimization (HIPO). Spearman's rank correlation and multiple regression analyses were conducted to assess the association between the parameters and the indices. The indices included clinical target volume (CTV) dose, organ-at-risk (OAR) dose, homogeneity, and conformity. Additionally, the correlation between optimization parameters and calculation time was investigated, along with a technique for efficiently generating treatment plans.

Results: "CTV Max Weight" and "OAR Max Weight" were the key parameters significantly affecting the indices. Increasing "CTV Max Weight" improved homogeneity but reduced the target coverage. The effect of "OAR Max Weight" on the dose reduction of CTVHR D90 (β = -0.59) was more significant than that on the dose reduction of OAR D2cc (β = -0.21). In addition, adjusting "CTV Min Weight" and "CTV Volume" could reduce the hyper-dose sleeve without increasing the OAR dose. A large number of normal tissue sampling points could negatively affect the dose distributions and increase the calculation times.

Conclusion: "CTV Max Weight" and "OAR Max Weight" were the most influential parameters in HIPO, significantly affecting dose-volume indices in IC/ISBT for uterine cervical cancer. Additionally, parameters that regulate the hyper-dose sleeve and needle-delivered dose were identified. The quality of treatment planning can be maintained and planning time reduced by appropriately optimizing these parameters.

Keywords: HIPO; IC/ISBT; brachytherapy; cervical cancer; inverse planning; optimization.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Association between the optimization parameters and the dose‐volume indices based on the Spearman's rank correlation analysis. The colors represent the different values of the correlation coefficient (r): red indicates a positive correlation (0 < r < 1); blue, a negative correlation (−1 < r < 0); and white, no correlation (r = 0).
FIGURE 2
FIGURE 2
Effect of each optimization parameter on the dose‐volume indices based on the multiple regression analysis. The colors represent the different values of the standardized regression coefficient (β): red indicates a positive effect (0 < β < 1); blue, a negative effect (−1 < β < 0); and white, no effect (β = 0).
FIGURE 3
FIGURE 3
Example of the effect of (a) “CTV Max Weight” and (b) “OAR Max Weight” on the dose distributions. The green, red, and blue lines represent the isodose curves of 300, 600, and 1200 cGy, respectively. The region of light blue is CTVHR. The brown, yellow, and red regions represent the rectum, bladder, and sigmoid colon, respectively. The arrows indicate where the 600 cGy isodose curve shrinks.
FIGURE 4
FIGURE 4
Effect of “CTV Min Weight” on the dose‐volume indices. Association between “CTV Min Weight” and (a) CTVHR D90; (b) CTVHR VCTV,100; (c) Dose nonuniformity index; (d) Homogeneity index.
FIGURE 5
FIGURE 5
Effect of “CTV Volume” on the dose‐volume indices. Association between CTV Min Weight” and (a) CTVHR D90; (b) rectum D2cc; (c) Dose nonuniformity index; (d) Homogeneity index.
FIGURE 6
FIGURE 6
Effect of the normal tissue sampling points on the dose‐volume indices. Association between “Normal tissue sampling points” and (a) CTVHR D90; (b) rectum D2cc; (c) conformity index; (d) calculation time by HIPO. Circles represent the longest calculation time for the largest tumor volume (163.5 cc).

Similar articles

References

    1. Pötter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC‐ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48–60. doi: 10.1016/j.ctro.2018.01.001 - DOI - PMC - PubMed
    1. Han K, Colson‐Fearon D, Liu ZA, Viswanathan AN. Updated trends in the utilization of brachytherapy in cervical cancer in the United States: a Surveillance, Epidemiology, and End‐Results Study. Int J Radiat Oncol Biol Phys. 2024;119(1):143–153. doi: 10.1016/j.ijrobp.2023.11.007 - DOI - PMC - PubMed
    1. Murakami N, Watanabe M, Uno T, et al. Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer. J Gynecol Oncol. 2023;34(3):e24. doi: 10.3802/jgo.2023.34.e24 - DOI - PMC - PubMed
    1. Takagawa Y, Machida M, Seto I, et al. Analysis of operative duration of image‐guided brachytherapy for cervical cancer. Strahlenther Onkol. 2025;201(5):520–527. doi: 10.1007/s00066-024-02297-5 - DOI - PubMed
    1. Karabis A, Giannouli S, Baltas D. 40 HIPO: a hybrid inverse treatment planning optimization algorithm in HDR brachytherapy. Radiother Oncol. 2005;76:S29. doi: 10.1016/s0167-8140(05)81018-7 - DOI

MeSH terms